Arcturus Therapeutics drops 5% due to weak quarterly revenue

LootboxPhobia · 2026-03-03T22:24:26+00:00

Arcturus Therapeutics announced a fourth-quarter loss of $1.03 per share, with revenue of $7.2 million, down 68% year-over-year. Despite a decrease in partnership revenue, the company continues to advance treatments for rare diseases and cystic fibrosis projects, with plans to initiate Phase 2 studies in 2026. Quarterly operating expenses decreased to $38.5 million, with cash reserves of $232 million, sufficient to sustain operations until 2028.

LootboxPhobia

2026-03-03 22:24:26

Abstract generation in progress

San Diego - Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) reported a fourth-quarter loss of $1.03 per share and revenue of $7.2 million. Revenue from collaborations, which is significant for this mRNA drug company, declined sharply compared to the same period last year. The stock fell 5.4% after the earnings release.

Revenue for the fourth quarter decreased 68% year-over-year, from $22.8 million last year to the current level, mainly due to reduced revenue from CSL collaborations as KOSTAIVE transitioned from development to commercialization. Full-year revenue for fiscal 2025 reached $82 million, down $70.3 million from fiscal 2024. The company posted a net loss of $29.1 million this quarter, compared to a net loss of $30 million in Q4 2024.

Joseph Payne, President and CEO of Arcturus, stated, “Arcturus continues to advance its portfolio of treatments for rare diseases. We look forward to reaching an agreement with regulatory agencies on the clinical development strategy for OTC deficiency, and to launching our Phase 2, 12-week cystic fibrosis (CF) study in the first half of 2026.”

The company reported positive progress on its ARCT-032 cystic fibrosis project, with the third cohort completing 28 days of dosing at 15 mg without safety or tolerability issues. The Safety Review Committee approved the project to move into a Phase 2, 12-week study planned for the first half of 2026, recruiting up to 20 Class I CF participants.

Total operating expenses for the fourth quarter were $38.5 million, down from $56.2 million in the same period last year, mainly due to lower manufacturing and clinical trial costs. Operating expenses for fiscal 2025 decreased from $248 million in fiscal 2024 to $158.3 million.

As of December 31, 2025, Arcturus reported cash, cash equivalents, and restricted cash of $232.8 million, extending its cash runway into the second quarter of 2028.

This article was translated with the assistance of artificial intelligence. For more information, please see our Terms of Use.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes